apalutamide联合激素治疗围手术期应用降低高危局部前列腺癌转移风险
Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death
apalutamide联合激素治疗围手术期应用显著降低高危局部前列腺癌患者转移或死亡风险(事件无进展生存率提升62%,转移或死亡风险降低51%,后续治疗延迟33个月)。该III期随机对照试验子研究(1:3,408例患者)由Dana-Farber癌症研究所主导,结果发表于《European Urology》2026年10月刊(DOI:10.1016/j.eururo.2026.10.016)。
原文明确给出apalutamide联合ADT围手术期应用与标准手术对比的III期随机试验数据,包括事件无进展生存率提升62%、转移或死亡风险降低51%等关键指标,为高危局部前列腺癌治疗决策提供直接证据支持。
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
The substudy, co-led by principal investigator Mary-Ellen Taplin, M.D., a medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, and published today in European Urology. Alberto Briganti, M.D., Ph.D., professor of urology at Vita-Salute San Raffaele University in Milan, Italy, presented the data at ESMO.
Previous Dana-Farber research led by Taplin, presented earlier this year at the American Society for Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine, found that apalutamide plus androgen-deprivation hormone therapy (ADT) prior to and after surgery showed significant promise for patients with high-risk localized prostate cancer.
Patients treated with the apalutamide plus hormone therapy regimen were nine times more likely to have little to no cancer present at surgery. The regimen reduced the risk of metastases or death by 20% and delayed subsequent therapy by 33 months compared with ADT alone.
The substudy compared the novel perioperative approach to standard of care, radical prostatectomy alone.
"Following the presentation of the PROTEUS results at ASCO, an important question remained: how does this regimen compare with standard-of-care prostatectomy? Addressing that question is essential to understanding the full clinical significance of these findings and determining how they can best inform treatment decisions for patients with high-risk localized prostate cancer," said Taplin. "This substudy demonstrated superior efficacy of perioperative apalutamide plus ADT over radical prostatectomy alone in high-risk localized/locally advanced prostate cancer, reinforcing the PROTEUS main study findings."
The PROTEUS substudy is a 1:3 randomized trial that included 408 patients with newly diagnosed high-risk localized or locally advanced prostate cancer and was designed to compare apalutamide plus ADT before and after surgery to standard-of-care radical prostatectomy. Apalutamide is approved for use in metastatic castration-sensitive prostate cancer and for nonmetastatic castration-resistant prostate cancer.
Participating patients received apalutamide plus ADT for six months before and after radical prostatectomy with pelvic lymph-node dissection or standard prostatectomy alone. The study's primary endpoint was event-free survival (events included PSA, clinical, PSMA-PET or conventional imaging relapse).
After a median follow-up of 37.8 months, the combination of apalutamide plus ADT and prostatectomy resulted in a 62% improvement in event-free survival and a 51% reduced risk of metastasis or death. The combination reduced the risk of starting a subsequent therapy by 71%, and 50% fewer patients started subsequent therapy by three years.
Side effects were consistent with data from previously reported studies.
"Combined evidence from the main and substudy support perioperative apalutamide plus ADT and prostatectomy as a potential treatment of choice in patients fit for surgery and systemic therapy," said Taplin.
Publication details
Alberto Briganti et al., Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy, European Urology (2026). DOI: 10.1016/j.eururo.2026.10.016
Journal information: European Urology , New England Journal of Medicine
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-patients-apalutamide-hormone-therapy-surgery.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com